About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Amylin CEO Got 11% Pay Rise Despite Losses; Company Paid $355K for Lawyer to Move House

By Jim Edwards | Apr 22, 2009

Combined executive pay at Amylin rose 10.2 percent last year even though the company lost 50 percent more money than it did the year before, according to a filing with the SEC. Amylin has not made a profit in the last five years, despite its revenues going from zero to $765 million.

Amylin CEO Daniel Bradbury’s total compensation went up 11 percent to $4.5 million. The company also gave its general counsel, Marcea Bland Lloyd, $355,510 just to move house from Dallas to San Diego.

Their base salaries all went up, and although they didn’t take bonuses, they all got bumps in “other” compensation — such as pay for untaken vacations. That’s where Lloyd’s moving bill came in:

In order to provide proper incentive for Ms. Lloyd to relocate to San Diego, we reimbursed her for certain relocation expenses including tax assistance to help offset the financial burden associated with relocating from Dallas, Texas. …

Included in “all other compensation” for Ms. Lloyd in 2008 include the sums of $26,154 representing relocation assistance and $328,756 representing taxable relocation expense reimbursements, including tax gross ups of $143,831 to help offset the high cost of relocating to San Diego.

Here’s the summary table:

  • Name, 2008 pay, 2007 pay
  • CEO Daniel M. Bradbury, $4.5 million, $4 million
  • CFO Mark G. Foletta, $1.3 million, $1.3 million
  • SVP R&D Orville Kolterman, $1.5 million, $1.5 million
  • General Counsel  Marcea Bland Lloyd, $1.2 million, $854,000
  • SVP HR Roger Marchetti, $1.4 million, $1.3 million
    Numbers are rounded, includes stock and options whose value may change.

Director compensation is also an issue; Carl Icahn and Eastbourne Capital, who are both trying to take over the company, say Amylin has not cut enough costs and directors are overpaid. They will be infuriated to learn that average director compensation is now $476.000. That’s even higher than it was last year, when average director costs were $440,000.

Chairman Joseph Cook Jr. got $424,000, Ginger Graham got $2.1 million. The lowest paid director got $245,000. Here’s a shot of the director summary table:

Amylin’s shareholder meeting is May 27.

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • Allergan CEO Pyott Received Pay Raise to $11.9 Million

    BNET Pharma - 245 days 15 hours 30 minutes ago

    Allergan CEO David Pyott received a 6 percent raise in total compensation last year, with his pay packet rising to $11.9 million. The top five executives of Allergan all got pay raises. Their total combined compensation rose 10 percent to $24 million. Over the year, Allergan fared well. Revenues rose to $4.4 billion from $3.9 billion. Net income...

  • Amylin CEO Bradbury Loses Chairman, Lead Director: Will He Be Next?

    BNET Pharma - 173 days 18 hours 42 minutes ago

    Can Amylin CEO Dan Bradbury survive now that he has lost his board chairman and lead director to nominees selected by insurgent investors Carl Icahn and Eastbourne Capital? It’s a legitimate question, especially when you add to the mix the fact that Amylin founder Howard Greene sides with the Axis of Icahn, which owns 21 percent of the...

  • Abbott CEO White Takes a Pay Cut

    BNET Pharma - 250 days 23 hours 28 minutes ago

    Abbott Labs CEO Miles White took a pay cut last year. His total compensation was only $28.3 million, down from $33.3 million the year before, per a proxy filing at the SEC. The cut came despite the judgment by Abbott's board that White "exceeded" his strategic and financial goals. Abbott's stock outperformed the S&P 500 last year. Revenue and...

  • Amylin Insists Byetta Doesn't Cause Cancer; Wall Street Doesn't Seem So Sure

    BNET Pharma - 216 days 13 hours 55 minutes ago

    Amylin CEO Daniel Bradbury may be wishing that Novo Nordisk’s failed competitor to its diabetes drug Byetta had actually been approved by the FDA. Had Novo’s liraglutide passed muster, no one would have gotten the jitters over whether Byetta gives you cancer or not. At Amylin’s conference call a couple of days ago, the cancer issue was...

  • Future of BI: web 2.0, mashups and guided search

    Silicon.com - 181 days 2 hours 23 minutes ago

    You are here: silicon.com > Research > Special Reports > Maximising Business Intelligence

Links from the Web Buzz:
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement